FDA Approves Tempus AI's Tumor-Only xT CDx, Launches IMS Consortium
TEM is trading near its 52-week low of $40.77 (8.0% above the low).
Summary
Tempus AI secured FDA approval for its tumor-only xT CDx assay, becoming the first lab with CDx approval for both tumor-only and tumor-normal genomic profiling. This expands its diagnostic reach and strengthens its competitive moat in precision oncology. The company also launched the IMS digital pathology consortium, adding a new growth vector. These developments follow the recent $1.5B Personalis acquisition and Q2 results showing 22% revenue growth and a shift to GAAP profitability. The FDA nod and consortium launch are fresh catalysts that could accelerate commercial traction and partnership opportunities.
At the time of this announcement, TEM was trading at $44.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.